Top

Cancer Causes & Control

Published in:

01-09-2009 | Original Paper

Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway

Authors: Richard M. Martin, Lars Vatten, David Gunnell, Pål Romundstad, Tom I. L. Nilsen

Published in: Cancer Causes & Control | Issue 7/2009

Abstract

Background

The metabolic syndrome has been suggested as a unifying link between a “western” lifestyle and an increased prostate cancer risk.

Methods

We assessed the associations of components of the metabolic syndrome with prostate cancer in a prospective cohort based on 29,364 Norwegian men followed up for prostate cancer incidence and mortality from 1995–1997 to the end of 2005 in the second Nord Trøndelag Health Study (HUNT 2).

Results

During a mean 9.3 years follow-up, 687 incident prostate cancers were diagnosed, and 110 men died from prostate cancer. There was little evidence that baseline BMI, waist circumference, waist–hip ratio, total or HDL-cholesterol, triglycerides, presence of the metabolic syndrome, diabetes, antihypertensive use, or cardiovascular disease were associated with incident or fatal prostate cancer. There was weak evidence that raised blood pressure was associated with an increased risk: for each SD (12 mm) increase in diastolic blood pressure, there was an 8% (95% CI = 1–17%; p = 0.04) increased risk of incident prostate cancer.

Conclusions

We found little evidence to support the hypothesis that the metabolic syndrome or its components explains higher prostate cancer mortality rates in countries with a “western” diet and lifestyle. The positive association of blood pressure with prostate cancer warrants further investigation.

Parkin DM (2004) International variation. Oncogene 23(38):6329–6340. doi:10.1038/sj.onc.1207726 PubMedCrossRef

Yatani R, Shiraishi T, Nakakuki K et al (1988) Trends in frequency of latent prostate carcinoma in Japan from 1965–1979 to 1982–1986. J Natl Cancer Inst 80(9):683–687. doi:10.1093/jnci/80.9.683 PubMedCrossRef

Post PN, Straatman H, Kiemeney LA, Coebergh JW (1999) Increased risk of fatal prostate cancer may explain the rise in mortality in The Netherlands. Int J Epidemiol 28(3):403–408. doi:10.1093/ije/28.3.403 PubMedCrossRef

Janssen F, Kunst AE, for The Netherlands Epidemiology, Demography Compression of Morbidity research group (2005) Cohort patterns in mortality trends among the elderly in seven European countries, 1950–99. Int J Epidemiol 34(5):1149–1159. doi:10.1093/ije/dyi123 PubMedCrossRef

Yu H, Harris RE, Gao YT, Gao R, Wynder EL (1991) Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States. Int J Epidemiol 20(1):76–81. doi:10.1093/ije/20.1.76 PubMedCrossRef

Hsing AW, Devesa SS (2001) Trends and patterns of prostate cancer: What do they suggest? Epidemiol Rev 23(1):3–13PubMed

Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37(12):1595–1607. doi:10.2337/diabetes.37.12.1595 PubMedCrossRef

Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, for the Conference Participants (2004) Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition. Circulation 109(3):433–438. doi:10.1161/01.CIR.0000111245.75752.C6 PubMedCrossRef

Giovannucci E (2003) Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 35(11/12):694–704

10.

Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH (2002) Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev 3(4):303–308. doi:10.1046/j.1467-789X.2002.00081.x PubMedCrossRef

11.

Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-1, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353. doi:10.1016/S0140-6736(04)16044-3 PubMedCrossRef

12.

Fan W, Yanase T, Morinaga H et al (2007) Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem 282(10):7329–7338. doi:10.1074/jbc.M610447200 PubMedCrossRef

13.

Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA 287(3):356–359. doi:10.1001/jama.287.3.356 PubMedCrossRef

14.

Hammarsten J, Hogstedt B (2004) Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 13(1):47–55. doi:10.1080/08037050310025735 PubMedCrossRef

15.

Freedland SJ, Platz EA (2007) Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29:88–97. doi:10.1093/epirev/mxm006 PubMedCrossRef

16.

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625–1638. doi:10.1056/NEJMoa021423 PubMedCrossRef

17.

Wright ME, Chang SC, Schatzkin A et al (2007) Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109(4):675–684. doi:10.1002/cncr.22443 PubMedCrossRef

18.

Pischon T, Boeing H, Weikert S et al (2008) Body size and risk of prostate cancer in the european prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 17(11):3252–3261. doi:10.1158/1055-9965.EPI-08-0609 PubMedCrossRef

19.

Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA (2007) Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 109(5):875–881. doi:10.1002/cncr.22461 PubMedCrossRef

20.

Wuermli L, Joerger M, Henz S et al (2005) Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 8(4):316–320. doi:10.1038/sj.pcan.4500834 PubMedCrossRef

21.

Lund Haheim L, Wisloff TF, Holme I, Nafstad P (2006) Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 164(8):769–774. doi:10.1093/aje/kwj284 PubMedCrossRef

22.

Browning DR, Martin RM (2007) Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120(4):833–843. doi:10.1002/ijc.22366 PubMedCrossRef

23.

Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL (2001) Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 11(8):534–542. doi:10.1016/S1047-2797(01)00246-0 PubMedCrossRef

24.

Gann PH, Daviglus ML, Dyer AR, Stamler J (1995) Heart rate and prostate cancer mortality: results of a prospective analysis. Cancer Epidemiol Biomarkers Prev 4(6):611–616PubMed

25.

Freeman MR, Solomon KR (2004) Cholesterol and prostate cancer. J Cell Biochem 91(1):54–69. doi:10.1002/jcb.10724 PubMedCrossRef

26.

Friedman GD (1997) Blood pressure and heart rate: no evidence for a positive association with prostate cancer. Ann Epidemiol 7(7):486–489. doi:10.1016/S1047-2797(97)00083-5 PubMedCrossRef

27.

Bidoli E, Talamini R, Bosetti C et al (2005) Macronutrients, fatty acids, cholesterol and prostate cancer risk. Ann Oncol 16(1):152–157. doi:10.1093/annonc/mdi010 PubMedCrossRef

28.

Niemi M, Kervinen K, Kiviniemi H et al (2000) Apolipoprotein E phenotype, cholesterol and breast and prostate cancer. J Epidemiol Community Health 54(12):938–939. doi:10.1136/jech.54.12.938 PubMedCrossRef

29.

MacInnis RJ, English DR, Gertig DM, Hopper JL, Giles GG (2003) Body size and composition and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 12(12):1417–1421PubMed

30.

MacInnis RJ, English DR (2006) Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 17(8):989–1003. doi:10.1007/s10552-006-0049-z PubMedCrossRef

31.

Borugian MJ, Spinelli JJ, Sun Z et al (2007) Prediagnostic C-peptide and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16(10):2164–2165. doi:10.1158/1055-9965.EPI-07-0495 PubMedCrossRef

32.

Moore SC, Leitzmann MF, Weinstein SJ et al (2007) Insulin resistance-related gene polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16(6):1315–1317. doi:10.1158/1055-9965.EPI-07-0191 PubMedCrossRef

33.

National Cholesterol Education Program Expert Panel (2002) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106(25):3143

34.

Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE (2002) Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 87(3):978–982. doi:10.1210/jc.87.3.978 PubMedCrossRef

35.

Kom EL, Graubard BI, Midthune D (1997) Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 145(1):72–80

36.

Zuccolo L, Harris R, Gunnell D et al (2008) Height and prostate cancer risk: a large nested case–control study (ProtecT) and meta-analysis. Cancer Epidemiol Biomarkers Prev 17(9):2325–2336. doi:10.1158/1055-9965.EPI-08-0342 PubMedCrossRef

37.

Nilsen TI, Romundstad PR, Vatten LJ (2006) Recreational physical activity and risk of prostate cancer: a prospective population-based study in Norway (the HUNT study). Int J Cancer 119(12):2943–2947. doi:10.1002/ijc.22184 PubMedCrossRef

38.

Makinen T, Karhunen P, Aro J, Lahtela J, Maattanen L, Auvinen A (2008) Assessment of causes of death in a prostate cancer screening trial. Int J Cancer 122(2):413–417. doi:10.1002/ijc.23126 PubMedCrossRef

39.

Newschaffer CJ, Otani K, McDonald MK, Penberthy LT (2000) Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 92(8):613–621. doi:10.1093/jnci/92.8.613 PubMedCrossRef

40.

Miller AB, Yurgalevitch S, Weissfeld L (2000) Death review process in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 21(6, supplement 1):400S–406S. doi:10.1016/S0197-2456(00)00095-7 PubMedCrossRef

41.

Hernes E, Harvei S, Glattre E, Gjertsen F, Fossa SD (2005) High prostate cancer mortality in Norway: influence of cancer registry information? APMIS 113(7–8):542–549. doi:10.1111/j.1600-0463.2005.apm_245.x PubMedCrossRef

42.

Harvei S, Tretli S, Langmark F (1996) Quality of prostate cancer data in the cancer registry of Norway. Eur J Cancer 32(1):104–110. doi:10.1016/0959-8049(95)00501-3 CrossRef

43.

Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC (2007) Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 121(7):1571–1578. doi:10.1002/ijc.22788 PubMedCrossRef

44.

Albertsen PC, Hanley JA, Fine J (2005) 20-Year outcomes following conservative management of clinically localized prostate cancer. J Am Med Assoc 293(17):2095–2101. doi:10.1001/jama.293.17.2095 CrossRef

45.

Hsing AW, Sakoda LC, Chua SC Jr (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86(3):S843–S857PubMed

46.

Stattin P, Kaaks R (2003) Re: insulin resistance and prostate cancer risk. J Natl Cancer Inst 95(14):1086–1087PubMedCrossRef

47.

Stattin P, Soderberg S, Hallmans G et al (2001) Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 86(3):1341–1345. doi:10.1210/jc.86.3.1341 PubMedCrossRef

48.

Stocks T, Lukanova A, Rinaldi S et al (2007) Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer 120(12):2678–2686. doi:10.1002/ijc.22587 PubMedCrossRef

49.

Tande AJ, Platz EA, Folsom AR (2006) The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 164(11):1094–1102. doi:10.1093/aje/kwj320 PubMedCrossRef

50.

Ness KK, Oakes JM, Punyko JA, Baker KS, Gurney JG (2005) Prevalence of the metabolic syndrome in relation to self-reported cancer history. Ann Epidemiol 15(3):202–206. doi:10.1016/j.annepidem.2004.07.092 PubMedCrossRef

51.

Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT (2004) Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 13(10):1646–1650PubMed

52.

Dalton M, Cameron AJ, Zimmet PZ et al (2003) Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J Intern Med 254(6):555–563. doi:10.1111/j.1365-2796.2003.01229.x PubMedCrossRef

53.

Karter AJ, D’Agostino RB, Mayer-Davis EJ et al (2005) Abdominal obesity predicts declining insulin sensitivity in non-obese normoglycaemics: the insulin resistance atherosclerosis study (IRAS). Diabetes Obes Metab 7(3):230–238. doi:10.1111/j.1463-1326.2004.00441.x PubMedCrossRef

54.

Ohlson LO, Larsson B, Svardsudd K et al (1985) The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 34(10):1055–1058. doi:10.2337/diabetes.34.10.1055 PubMedCrossRef

55.

Richelsen B, Pedersen SB (1995) Associations between different anthropometric measurements of fatness and metabolic risk parameters in non-obese, healthy, middle-aged men. Int J Obes Relat Metab Disord J Int Assoc Stud Obes 19(3):169–174

56.

Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ (2001) Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 10(4):345–353PubMed

57.

Andersson SO, Wolk A, Bergstrom R et al (1997) Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 89(5):385–389. doi:10.1093/jnci/89.5.385 PubMedCrossRef

Title: Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway
Authors: Richard M. Martin
Lars Vatten
David Gunnell
Pål Romundstad
Tom I. L. Nilsen
Publication date: 01-09-2009
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 7/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-009-9319-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2009

Spatial cluster analysis of early stage breast cancer: a method for public health practice using cancer registry data

Tonsillectomy may be an indicator of low vitamin D status, a risk factor for cancer later in life

Indirect method to estimate specific Hispanic group cancer rates

The epidemiology of triple-negative breast cancer, including race

The association of atopic diseases with breast, prostate, and colorectal cancers: a meta-analysis

Phytoestrogen consumption and endometrial cancer risk: a population-based case–control study in New Jersey

Keynote webinar | Spotlight on antibody–drug conjugates in cancer